抗病毒药物治疗肝纤维化的市场规模、份额和增长分析：按病毒发病机制、药物类别/作用机制、纤维化阶段、最终用户和地区划分－2026-2033年产业预测

2024 年全球用于治疗肝纤维化的抗病毒药物市场价值为 220 亿美元，预计到 2033 年将从 2025 年的 244.2 亿美元增长至 562.8 亿美元，预测期（2026-2033 年）的复合年增长率为 11.0%。

全球抗病毒药物肝纤维化市场的主要驱动力是慢性病毒性肝炎盛行率的不断上升。慢性病毒性肝炎会增加肝纤维化进展的风险，从而持续催生对有效治疗方法的需求。乙型和丙型肝炎病毒感染的持续存在凸显了预防肝硬化和肝细胞癌等併发症的紧迫性，推动了抗病毒药物研发领域的大量投资。市场正从疗效有限的干扰素疗法转向强效的直接抗病毒药物（DAA）和核苷类似物，这些药物已被证实能够透过抑制病毒来减轻肝纤维化。此外，筛检和诊断技术的进步使得早期疗育成为可能，从而最大限度地减少了晚期併发症。同时，人工智慧正在透过改进标靶识别、生物标记发现和临床试验设计，革新药物研发，最终扩大商业性机会，并使全球患者能够获得多种多样的抗病毒疗法。

全球抗病毒药物肝纤维化的市场驱动因素

病毒性肝炎发生率的上升显着增加了肝纤维化风险的患者数量，导致人们对有效抗病毒疗法的关注度和需求日益增长。疾病盛行率的激增正在影响研究重点，并加速药物研发资金的投入。相关人员积极将抗病毒疗法纳入治疗通讯协定，从而提高了临床认知度，并开展了更积极的公众宣传活动。随着早期诊断和治疗方法的普及，以及医疗服务提供者和保险公司寻求能够阻止病情发展为严重肝病并减轻长期医疗需求的解决方案，这些努力正在推动市场持续成长。

全球抗病毒药物肝纤维化市场面临的限制因素

全球抗病毒药物治疗肝纤维化的市场面临诸多限制因素，包括治疗费用飙升和保险报销范围有限，导致患者难以获得所需的治疗。当患者面临高额自付费用或保险覆盖范围不确定时，医疗服务提供者可能会延迟开立抗病毒药物处方或考虑其他治疗方案，从而阻碍市场渗透。此外，保险公司和医疗机构设定的严格合格标准进一步限制了符合治疗条件的患者群体，降低了药物的商业性吸引力，并阻碍了产品的大规模上市。这些准入障碍不仅减缓了收入成长，也阻碍了投资，并妨碍了创新治疗方法被纳入肝​​纤维化患者的标准治疗方案。

全球抗病毒药物肝纤维化的市场趋势

全球肝纤维化抗病毒药物市场正经历着向精准医疗的显着转变，强调基于分子谱分析和生物标记选择的个人化治疗策略。研发人员日益专注于开发能够特异性针对不同病毒基因型和特定纤维化路径的抗病毒药物。与诊断试剂生产商合作开发伴随诊断试剂也日益普遍，这透过增强临床疗效和减少不必要的治疗来提高患者照护品质。此外，保险公司和医疗服务提供者正优先考虑以疗效为导向的疗法，并加大对创新研发管线和先进商业模式的投资，以满足患者的个人需求。这些措施最终将提升整体治疗效果和患者满意度。

目录

介绍

• 调查目的
• 市场定义和范围

调查方法

• 研究过程
• 二级资料和一级资料的方法
• 市场规模估算方法

执行摘要

• 全球市场展望
• 市场主要亮点
• 细分市场概览
• 竞争环境概述

市场动态及展望

• 总体经济指标
• 促进者和机会
• 抑制因素和挑战
• 供给面趋势
• 需求面趋势
• 波特的分析和影响

关键市场分析

• 关键成功因素
• 影响市场的因素
• 主要投资机会
• 生态系测绘
• 2025年市场魅力指数
• PESTLE分析
• 监理情势

全球抗病毒药物治疗肝纤维化的市场规模：依病毒病因分类

• 针对乙型肝炎病毒（HBV）
• 针对丙型C型肝炎病毒（HCV）

全球用于治疗肝纤维化的抗病毒药物市场规模：按药物类别/作用机制划分

• 核苷/核苷酸类似物（NrtIs）
• 直接作用抗病毒药物（DAAs）
• 干扰素疗法

全球用于治疗肝纤维化的抗病毒药物市场规模：按纤维化进展阶段划分

• 初期
• 进行性纤维化/肝硬化

用于治疗肝纤维化的抗病毒药物的全球市场规模：按最终用户划分。

• 肝病中心
• 诊断和调查机构
• 专科药房

用于治疗肝纤维化的抗病毒药物的全球市场规模：按地区划分

• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太国家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲国家
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲国家

竞争资讯

• 前五大公司对比
• 主要企业2025年的市场定位
• 主要市场公司采取的策略
• 近期市场趋势
• 企业市场占有率分析，2025 年
• 主要企业的完整公司简介
  • 公司详情
  • 产品系列分析
  • 按细分市场进行企业市占率分析
  • 销售收入年比比较（2023-2025 年）

主要企业简介

• Gilead Sciences
• AbbVie
• Merck & Co.
• Bristol Myers Squibb
• Intercept Pharmaceuticals
• Hepion Pharmaceuticals
• Genfit
• Novartis
• Echosens
• Promethera Biosciences
• Syneos Health
• TFF Pharmaceuticals
• Enanta Pharmaceuticals
• Sernova Corp
• Immuron
• Aegerion Pharmaceuticals
• Zymeworks
• DURECT Corporation
• Addex Therapeutics
• Hologic

结论与建议

Global Liver Fibrosis Antiviral Agents Market size was valued at USD 22.0 Billion in 2024 and is poised to grow from USD 24.42 Billion in 2025 to USD 56.28 Billion by 2033, growing at a CAGR of 11.0% during the forecast period (2026-2033).

The global liver fibrosis antiviral agents market is primarily driven by the increasing prevalence of chronic viral hepatitis, which heightens the risk of fibrotic progression and creates ongoing demand for effective treatments. The persistence of hepatitis B and C infections has emphasized the urgency of preventing complications like cirrhosis and hepatocellular carcinoma, fostering significant investment in antiviral research. The market has transitioned from less effective interferon-based therapies to robust direct-acting antivirals and nucleos(t)ide analogs that have demonstrated the capability of reducing fibrosis through viral suppression. Additionally, enhanced screening and diagnostics have facilitated early intervention and minimized advanced-stage complications. Meanwhile, AI is revolutionizing drug discovery by improving target identification, biomarker discovery, and trial design, ultimately expanding commercial opportunities and patient access to diverse antiviral therapies worldwide.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Liver Fibrosis Antiviral Agents market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Liver Fibrosis Antiviral Agents Market Segments Analysis

Global liver fibrosis antiviral agents market is segmented by viral etiology, drug class/mechanism, fibrosis stage, end-user and region. Based on viral etiology, the market is segmented into Hepatitis B Virus (HBV) Directed and Hepatitis C Virus (HCV) Directed. Based on drug class/mechanism, the market is segmented into Nucleoside/Nucleotide Analogues (NrtIs), Direct-Acting Antivirals (DAAs) and Interferon Therapies. Based on fibrosis stage, the market is segmented into Early Stage and Advanced Fibrosis/Cirrhosis. Based on end-user, the market is segmented into Hepatology Centers, Diagnostic & Research Institutes and Specialized Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Liver Fibrosis Antiviral Agents Market

The increasing incidence of viral hepatitis has significantly broadened the number of patients susceptible to liver fibrosis, thereby intensifying the focus on and demand for effective antiviral treatments. This surge in disease prevalence drives research priorities and accelerates funding for drug development. Stakeholders are motivated to incorporate antiviral therapies into treatment protocols, leading to improved clinical awareness and outreach initiatives. Such efforts result in earlier diagnosis and increased adoption of therapies, facilitating continuous market growth as healthcare providers and payers look for solutions that can halt the progression to severe liver disease and lessen long-term healthcare requirements.

Restraints in the Global Liver Fibrosis Antiviral Agents Market

The Global Liver Fibrosis Antiviral Agents market faces significant constraints due to high treatment costs and limited reimbursement options, which hinder patient access to necessary therapies. When patients encounter considerable out-of-pocket expenses or inconsistent coverage, healthcare providers may opt to delay prescribing antiviral medications or consider alternative treatment strategies, ultimately reducing market uptake. Additionally, payers and healthcare systems that enforce strict eligibility criteria further limit the eligible population for treatment, diminishing commercial appeal and discouraging extensive product launches. Such access barriers not only slow revenue growth but also impede investments and the integration of innovative therapies into standard care for those affected by liver fibrosis.

Market Trends of the Global Liver Fibrosis Antiviral Agents Market

The Global Liver Fibrosis Antiviral Agents market is witnessing a significant trend towards precision therapeutics, emphasizing personalized treatment strategies driven by molecular profiling and biomarker selection. Developers are increasingly focusing on creating antiviral agents that specifically address various viral genotypes and target distinct fibrotic pathways. Collaborations with diagnostics companies to develop companion tests are becoming more common, enhancing patient care by improving clinical responses and minimizing unnecessary treatments. Additionally, payers and healthcare providers are prioritizing outcome-focused therapies, prompting investment in innovative pipeline assets and advanced commercial models that cater to the unique needs of patients, thus enhancing overall treatment efficacy and satisfaction.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Liver Fibrosis Antiviral Agents Market Size by Viral Etiology & CAGR (2026-2033)

• Market Overview
• Hepatitis B Virus (HBV) Directed
• Hepatitis C Virus (HCV) Directed

Global Liver Fibrosis Antiviral Agents Market Size by Drug Class/Mechanism & CAGR (2026-2033)

• Market Overview
• Nucleoside/Nucleotide Analogues (NrtIs)
• Direct-Acting Antivirals (DAAs)
• Interferon Therapies

Global Liver Fibrosis Antiviral Agents Market Size by Fibrosis Stage & CAGR (2026-2033)

• Market Overview
• Early Stage
• Advanced Fibrosis/Cirrhosis

Global Liver Fibrosis Antiviral Agents Market Size by End-User & CAGR (2026-2033)

• Market Overview
• Hepatology Centers
• Diagnostic & Research Institutes
• Specialized Pharmacies

Global Liver Fibrosis Antiviral Agents Market Size & CAGR (2026-2033)

• North America (Viral Etiology, Drug Class/Mechanism, Fibrosis Stage, End-User)
  • US
  • Canada
• Europe (Viral Etiology, Drug Class/Mechanism, Fibrosis Stage, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Viral Etiology, Drug Class/Mechanism, Fibrosis Stage, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Viral Etiology, Drug Class/Mechanism, Fibrosis Stage, End-User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Viral Etiology, Drug Class/Mechanism, Fibrosis Stage, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Gilead Sciences
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Intercept Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hepion Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genfit
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Echosens
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Promethera Biosciences
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Syneos Health
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• TFF Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Enanta Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sernova Corp
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Immuron
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aegerion Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zymeworks
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• DURECT Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Addex Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hologic
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations